Electronic Supplementary Information

TBA-OH Catalysed 1,4-Addition of Hydroxide into α,β-Unsaturated Ketone by Microwave Irradiation in Water

Hyejeong Lee and Chul-Ho Jun*

Department of Chemistry, Yonsei University, 50 Yonseiro, Seodaemun-gu, Seoul 120-749, Korea.

Contents

1.	General	S2
2.	Materials	S 2
3.	Experimental	S 3

- A. Microwave-assisted C-C double bond cleavage of various α,β-unsaturated compounds by TBA-OH catalyst in water (Table 2)
- **B.** A typical procedure for the formation of benzimidazole derivatives via trapping of di-aldehyde (Table 3)
- C. A typical procedure for the formation of multi-substituted phenol from alkyne and diketone with base catalyst (Table 4)
- D. Characterization data (2b, 2c, 3a-3d, 4a-4c, 6a-6c, 7a, 7b, 10a-10g, 11a)
- 4. ¹H and ¹³C NMR spectra of new compounds S8

1. General

Flash column chromatography was performed using E. Merck 230-400 mesh silica gel and column chromatography was monitored by analytical thin-layer chromatography (TLC) carried out on 0.25 Merck silica gel plates (60F-254) using UV light as a visualizing agent, p-anisaldehyde and KMnO₄ solution as staining solutions, and heat as developing agent. Microwave experiments were performed in a CEM Discover instrument with appropriate internal IR temperature control using 10 mL Pyrex vials. The reaction temperature and microwave power were monitored by computer, and a 10 mL thick walled Pyrex reaction vessel with Teflon septa with a crimp top was used as a reaction vessel. Gas chromatographic analyses were performed on Agilent 7890A instrument with FID detector and an Agilent HP-5 capillary column. Mass chromatography analyses were performed on Agilent 5975C instrument and an Agilent HP-5MS column. IR spectra were recorded using a Bruker Vertex 70 FT-IR spectrometer. ¹H NMR and ¹³C NMR were recorded on a Bruker Advance II/DPX 400(400 MHz¹H, 100 MHz¹³C) spectrometers with chemical shifts reported relative to residual deuterated solvent peaks. ¹H NMR spectra were referenced to CDCl₃ (for ¹H, δ = 7.26) as internal standard, and are reported as follows: chemical shift multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet). ¹³C NMR spectra were referenced to the residual CDCl₃ (for 13 C, $\delta = 77.26$) as internal standard]. High-resolution Mass spectra were provided by YCRF Yonsei university.

2. Materials

Most commercially available reagent grade chemicals [1a-h, 5, 8a-c, 9a-c, NaOH, tetrabutylammonium hydroxide (TBA-OH), tetrabutyl ammonium chloride (TBA-Cl), K_2CO_3 , amberlyst A26, HCl, moecular sieve, phosphotungstic acid, amberlyst 16, AlCl₃ and MeOH] were purchased from Aldrich Chemical Company, TCI, and Burdick and Jackson, and used as received without further purification unless otherwise stated.

3. Experimental

A. Microwave-assisted C-C double bond cleavage of various α , β -unsaturated compounds by TBA-OH catalyst in water (Table 2)

- C-C double bond cleavage of 3-(anthracen-9-yl)acrylaldehyde (1a) by TBA-OH (entry 1): To a 10 ml microwave vessel was added 3-(anthracen-9-yl)acrylaldehyde (1a, 92.9 mg, 0.40 mmol), TBA-OH (64.0 mg, 0.08 mmol) and H₂O (400 mg, 22.2 mmol). The mixture was heated at 150 °C for 10 min with stirring under microwave irradiation. After cooling the vessel to room temperature, the crude mixture was purified by column chromatography (*n*-hexane:ethyl acetate = 5:1) on silica gel to give anthracene-9-carbaldehyde (**3a**, 76.6 mg, 93 %) as a pale yellow powder.

B. A typical procedure for the formation of benzimidazole derivatives via trapping of aldehyde (Table 3)

- Formation of 2-methyl-benzimidazole (6a) and 2-(anthracen-9-yl)benzimidazole (7a) from 3-(anthracen-9-yl)acrylaldehyde (1a) with benzene-1,2-diamine (5) (entry 1): To a 10 ml microwave vessel was added 3-(anthracen-9-yl)acrylaldehyde (1a, 92.9 mg, 0.40 mmol), benzene-1,2-diamine (5, 95.2 mg, 0.88 mmol), TBA-OH (64.0 mg, 0.08 mmol) and H₂O (400 mg, 22.2 mmol). The mixture was heated at 150 °C for 10 min with stirring under microwave irradiation. After cooling the vessel to room temperature, the crude mixture was purified by column chromatography (*n*-hexane:ethyl acetate = 5:1) on silica gel to give 2-methyl-benzimidazole (**6a**, 32.7 mg, 62%) and 2-(anthracen-9-yl)benzimidazole (**7a**, 68.2 mg, 58%).

C. A typical procedure for the formation of multi-substituted phenol from alkyne and diketone with base catalyst (Table 4)

- Formation of (3-hydroxy-5-methyl-[1,1'-biphenyl]-2-yl)phenylmethanone (10a) from 4phenylbut-3-yn-2-one (8a) and 1-phenylbutane-1,3-dione (9a) (entry 1): To a 10 ml microwave vessel was added (3-hydroxy-5-methyl-[1,1'-biphenyl]-2-yl)phenylmethanone (8a, 57.6 mg, 0.40 mmol), 1-phenylbutane-1,3-dione (9a, 71.3 mg, 0.44 mmol), TBA-OH (64.0 mg, 0.08 mmol) and H₂O (400 mg, 22.2 mmol). The mixture was heated at 100 °C for 10 min with stirring under microwave irradiation. After cooling the vessel to room temperature, the crude mixture was purified by column chromatography (*n*-hexane:ethyl acetate = 5:1) on silica gel to give (3-hydroxy-5-methyl[1,1'-biphenyl]-2-yl)phenylmethanone (**10a**, 103.7 mg, 90%).

D. Characterization data (2b, 2c, 3a-3d, 4a-4c, 6a-6c, 7a, 7b, 10a-10g)

Acetophenone (2b) [CAS No. 98-86-2] ¹H NMR (400 MHz, CDCl₃) δ 7.94-7.96 (m, 2H), 7.53-7.58 (m, 1H), 7.44-7.47 (m, 2H), 2.60 (s, 3H).

1-(4-Methoxyphenyl)ethanone (2c) [CAS No. 100-06-1] ¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 3.86 (s, 3H), 2.55 (s, 3H).

Anthracene-9-carbaldehyde (3a) [CAS No. 642-31-9] ¹H NMR (400 MHz, CDCl₃) δ 8.96 (d, J = 8.8 Hz, 2H), 8.65 (s, 1H), 8.03 (d, J = 8.4 Hz, 2H), 7.66 (t, J = 6.8 Hz, 2H), 7.53 (t, J = 7.6 Hz, 2H).

6-Methylhept-5-en-2-one (3b) [CAS No. 110-93-8] ¹H NMR (400 MHz, CDCl₃) δ 5.06 (t, *J* = 7.2 Hz, 1H), 2.45 (t, *J* = 7.2 Hz, 2H), 2.29-2.24 (m, 2H), 2.14 (s, 3H), 1.68 (s, 6H).

Benzaldehyde (3c) [CAS No. 100-52-7] ¹H NMR (400 MHz, CDCl₃) δ 10.0 (s, 1H), 7.87 (d, J = 6.8 Hz, 2H), 7.61 (t, J = 7.2 Hz, 1H), 7.51 (t, J = 7.6 Hz, 2H).

4-Methoxybenzaldehyde (3d) [CAS No. 123-11-5] ¹H NMR (400 MHz, CDCl₃) δ 9.87 (s, 1H), 7.82 (d, *J* = 8.8 Hz, 2H), 6.99 (d, *J* = 8.4 Hz, 2H), 3.87 (s, 3H).

1,3,5-Triphenylpentane-1,5-dione (4a) [CAS No. 6263-84-9] ¹H NMR (400 MHz, CDCl₃) δ 7.95-7.92 (m, 4H), 7.51 (t, *J* = 7.2 Hz, 2H), 7.42-7.38 (m, 4H), 7.30-7.23 (m, 4H), 7.18-7.14 (m, 1H), 4.12-4.05 (m, 1H), 3.48 (dd, *J* = 16.8 Hz, *J* = 6.8 Hz, 2H), 3.35 (dd, *J* = 16.4 Hz, *J* = 6.8 Hz, 2H).

3-(4-Methoxyphenyl)-1,5-diphenylpentane-1,5-dione (4b) [CAS No. 39659-76-2] ¹H NMR (400 MHz, CDCl₃) δ 7.95-7.93 (m, 4H), 7.53 (t, *J* = 7.6 Hz, 2H), 7.45-7.41 (m, 4H), 7.20 (d, *J* = 8.0 Hz, 2H), 6.80 (d, *J* = 8.8 Hz, 2H), 4.04-4.01 (m, 1H), 3.73 (s, 3H), 3.47 (dd, *J* = 16.4 Hz, *J* = 6.8 Hz, 2H), 3.31 (dd, *J* = 16.4 Hz, *J* = 7.2 Hz, 2H).

1,5-bis(**4-Methoxyphenyl**)-**3-phenylpentane-1,5-dione** (**4c**) **[CAS No. 82672-13-7]** ¹H NMR (400 MHz, CDCl₃) δ 7.95-7.93 (m, 4H), 7.27-7.26 (m, 4H), 7.19-7.14 (m, 1H), 6.92-6.89 (m, 4H), 4.05-4.02 (m, 1H), 3.84 (s, 6H), 3.43 (dd, *J* = 16.0 Hz, *J* = 6.8 Hz, 2H), 3.27 (dd, *J* = 16.0 Hz, *J* = 6.8 Hz, 2H).

2-methyl-benzimidazole (6a) [CAS No. 615-15-6] ¹H NMR (400 MHz, CDCl₃) δ 10.94 (s, 1H), 7.51 (dd, J = 5.6 Hz, J = 3.2 Hz, 2H), 7.18 (dd, J = 5.6 Hz, J = 2.8 Hz, 2H), 2.58 (s, 3H).

2-Ethyl-benzimidazole (6b) [CAS No. 1848-84-6] ¹H NMR (400 MHz, CDCl₃) δ 11.49 (s, 1H), 7.57 (dd, *J* = 4.9 Hz, *J* = 3.0 Hz, 2H), 7.21 (dd, *J* = 5.3 Hz, *J* = 3.0 Hz, 2H), 3.03 (q, *J* = 7.5 Hz, 2H), 1.45 (t, *J* = 7.6 Hz, 3H).

2-Hexyl-benzimidazole (6c) [CAS No. 5851-48-9] ¹H NMR (400 MHz, CDCl₃) δ 10.82 (s, 1H), 7.77 (dd, *J* = 6.0 Hz, *J* = 3.2 Hz, 2H), 7.37 (dd, *J* = 6.0 Hz, *J* = 3.2 Hz, 2H), 3.25 (t, *J* = 7.6 Hz, 2H), 2.00-1.94 (m, 2H), 1.36-1.21 (m, 6H), 0.78 (t, *J* = 7.2 Hz, 3H).

2-(Anthracen-9-yl)benzimidazole (7a) [CAS No. 81410-32-4] ¹H NMR (400 MHz, CDCl₃) δ 9.57

(s, 1H), 8.63 (d, *J* = 8.8 Hz, 2H), 7.87 (d, *J* = 8.0 Hz, 2H), 7.44-7.35 (m, 6H), 7.16 (d, *J* = 7.6 Hz, 2H).

2-Phenyl-benzimidazole (7b) [CAS No. 716-79-0] ¹H NMR (400 MHz, CDCl₃) δ 8.06 (dd, *J* = 8.0 Hz, *J* = 2.0 Hz, 2H), 7.65 (s, 1H), 7.52-7.47 (m, 3H), 7.30-7.26 (m, 3H).

(**3-Hydroxy-5-methyl-[1,1'-biphenyl]-2-yl)phenylmethanone** (**10a**) [CAS No. 1470369-40-4] ¹H NMR (400 MHz, CDCl₃) δ 9.95 (s, 1H), 7.35 (d, *J* = 8.4 Hz, 2H), 7.17-7.11 (m, 3H), 7.06-6.97 (m, 5H), 6.92 (s, 1H), 6.80 (s, 1H), 2.43 (s, 3H).

1-(3-Hydroxy-5-methyl-[1,1'-biphenyl]-2-yl)ethanone (**10b**) **[CAS No. 65053-04-5]** ¹H NMR (400 MHz, CDCl₃) δ 12.67 (s, 1H), 7.58 (d, *J* = 6.8 Hz, 2H), 7.44-7.37 (m, 3H), 7.06 (s, 1H), 6.94 (s, 1H), 2.65 (s, 3H), 2.62 (s, 3H).

(5'-Hydroxy-[1,1':3',1''-terphenyl]-2'-yl)phenylmethanone (10c) ¹H NMR (400 MHz, CDCl₃) δ 9.92 (s, 1H), 7.69 (d, J = 7.2 Hz, 2H), 7.47 (t, J = 7.2 Hz, 2H), 7.42-7.39 (m, 3H), 7.34 (d, J = 1.6 Hz, 1H), 7.23 (d, J = 1.6 Hz, 1H), 7.21-7.17 (m, 3H), 7.08-6.98 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 201.7, 160.5, 146.5, 145.1, 141.1, 139.8, 139.4, 132.2, 129.9, 129.6, 129.2, 128.7, 128.3, 127.9, 127.7, 127.5, 121.3, 120.0, 114.9; IR spectrum (CH₂Cl₂) 3331, 3082, 3060, 3030, 1735, 1669, 1623, 1440, 1401, 1268, 949 cm-1; HR-MS(ESI) calcd for C₂₅H₁₉O₂⁺ [M+H]⁺ 351.1380; found 351.1377.

(**5'-Hydroxy-[1,1':3',1''-terphenyl]-4'-yl)phenylmethanone** (**10d**) [CAS No. 7593-13-7] ¹H NMR (400 MHz, CDCl₃) δ 9.91 (s, 1H), 7.68 (d, *J* = 7.2 Hz, 2H), 7.47 (t, *J* = 7.2 Hz, 2H), 7.42-7.40 (m, 3H), 7.34 (d, *J* = 1.6 Hz, 1H), 7.23 (d, *J* = 1.2 Hz, 1H), 7.20-7.18 (m, 3H), 7.08-6.98 (m, 5H).

1-(5'-Hydroxy-[1,1':3',1''-terphenyl]-4'-yl)ethanone (**10e**) **[CAS No. 51522-45-3]** ¹H NMR (400 MHz, CDCl₃) δ 11.97 (s, 1H), 7.99 (d, *J* = 6.8 Hz, 2H), 7.55-7.37 (m, 8H), 7.24 (s, 1H), 6.86 (s, 1H), 1.87 (s, 3H).

(**3-Butyl-5-hydroxy-[1,1'-biphenyl]-4-yl)phenylmethanone** (**10f**) ¹H NMR (400 MHz, CDCl₃) δ 8.56 (s, 1H), 7.76 (d, *J* = 6.8 Hz, 2H), 7.64-7.56 (m, 3H), 7.46 (t, *J* = 8.0 Hz, 4H), 7.41-7.37 (m, 1H), 7.11 (d, J = 1.6 Hz, 1H), 7.05 (d, J = 1.6 Hz, 1H), 2.37 (t, J = 7.6 Hz, 2H), 1.42-1.35 (m, 2H), 1.09-1.00 (m, 2H), 0.70 (t, J = 7.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 201.0, 158.1, 145.8, 144.5, 140.1, 139.8, 133.3, 129.4, 129.1, 128.8, 128.4, 127.4, 122.4, 120.9, 113.4, 34.9, 34.2, 22.6, 13.8; IR spectrum (CH₂Cl₂) 3403, 3061, 3033, 2927, 1668, 1450, 1407, 1268, 1001 cm-1; HR-MS(ESI) calcd for C₂₃H₂₃O₂⁺ [M+H]⁺ 331.1693; found 331.1690.

1-(3-Butyl-5-hydroxy-[1,1'-biphenyl]-4-yl)ethanone (10g) ¹H NMR (400 MHz, CDCl₃) δ 11.8 (s, 1H), 7.62 (d, J = 1.6 Hz, 2H), 7.45 (t, J = 7.2 Hz, 2H), 7.41-7.37 (m, 1H), 7.07 (d, J = 2.0 Hz, 1H), 7.00 (d, J = 1.6 Hz, 1H), 2.95 (t, J = 8.0 Hz, 2H), 2.71 (s, 3H), 1.68-1.60 (m, 2H), 1.47-1.38 (m, 2H), 0.96 (t, J = 7.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 206.0, 162.4, 147.1, 145.1, 139.7, 129.1, 128.7, 127.4, 121.3, 120.8, 114.5, 36.2, 34.9, 32.7, 23.1, 14.1; IR spectrum (CH₂Cl₂) 3363, 2957, 2929, 2870, 1682, 1622, 1554, 1405, 1358, 1263, 1209, 1028 cm-1; HR-MS(ESI) calcd for C₁₈H₂₁O₂⁺ [M+H]⁺ 269.1536; found 269.1533.

(3-butoxy-5-methyl-[1,1'-biphenyl]-2-yl)phenylmethanone (11a) ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, *J* = 7.2 Hz, 2H), 7.44 (t, *J* = 7.6 Hz, 1H), 7.3 (t, *J* = 7.6 Hz, 2H), 7.26-7.24 (m, 2H), 7.21-7.16 (m, 3H), 6.85 (s, 1H), 6.77 (s, 1H), 3.89 (t, *J* = 6.4 Hz, 2H), 2.43 (s, 3H), 1.49-1.42 (m, 2H), 1.11-0.97 (m, 2H), 0.72 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.7, 156.8, 141.8, 140.6, 140.2, 138.8, 132.8, 129.4, 129.1, 128.3, 128.2, 127.4, 126.1, 123.2, 111.7, 68.3, 31.1, 22.0, 19.0, 13.8; IR spectrum (CH₂Cl₂) 3083, 3060, 3029, 2958, 2933, 2872, 1668, 1602, 1568, 1449, 927 cm-1; HR-MS(ESI) calcd for C₂₄H₂₅O₂⁺ [M+H]⁺ 345.1849; found 345.1948.



10a COSY DATA





S9

10a HSQC DATA





S11









